Thrive Health and Wellness, LLC

Has Thrive Health and Wellness, LLC received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Thrive Health and Wellness, LLC a warning letter naming tirzepatide, dated Feb 9, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” FDA has posted a close-out letter for that letter. openFDA also lists 8 drug recall reports for the firm naming semaglutide and tirzepatide.

FDA records in this index name Thrive Health and Wellness, LLC from May 21, 2025 to Feb 9, 2026.

Names in FDA records
Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado); Thrive Health and Wellness, LLC dba Thrive Health Solutions
Type named in FDA records
Compounding pharmacy
FDA warning letters
1
Drug recall reports
8
Drugs named
Semaglutide, Tirzepatide
Latest record
Feb 9, 2026

FDA warning letters

Later letters FDA listsLetter
Feb 9, 2026Compounding Pharmacy/Adulterated Drug ProductsTirzepatideClose-out letter, Aug 6, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

Record
May 21, 2025Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0480-2025
May 21, 2025Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0479-2025
May 21, 2025Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0481-2025
May 21, 2025Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0484-2025
May 21, 2025Tirzepatide/Cyanocobalamin Injectable, 15mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0485-2025
May 21, 2025Tirzepatide Injections, 10mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0482-2025
May 21, 2025Tirzepatide/Cyanocobalamin Injectable, 30mg/1mg/mL (15mg/0.5mg/0.5mL), pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo...Lack of Assurance of SterilityClass IIOngoingD-0486-2025
May 21, 2025Tirzepatide Injections, 20mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112Lack of Assurance of SterilityClass IIOngoingD-0483-2025

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Thrive Health and Wellness, LLC, dba Thrive Health Solutions, Englewood, CO (503A)

2 listed actions, including 1 Form 483 and 1 warning letter (2025 to 2026).

Document
Feb 9, 2026Warning letterWarning Letter (02/09/2026)fda.gov
Apr 3, 2025Form 483483 issued 04/03/2025fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Thrive Health Solutions (Thrive Health and Wellness, LLC), Englewood, CO.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.